NEWS

WIRES

OTHER

Biomoda Allowed Patent in Canada

Allowed by the Canadian Intellectual Property Office, Canadian patent application 2,429,526, "Compositions and Methods for Detecting Pre-Cancerous Conditions In Cell And Tissue Samples Using 5, 10, 15, 20-Tetrakis (Carboxyphenyl) Porphine," is similar to Biomoda's U.S. patent 6,838,248, which was issued in 2005. Foreign equivalents are now effective in Canada, Mexico, Japan and Australia and are pending in Europe.

"With the World Health Organization reporting more than 5 million tobacco-related deaths every year, lung cancer mortality is clearly a global issue," said Biomoda President John Cousins. "Protecting our intellectual property at the international level is the first step toward a global strategy for the commercialization and marketing of the CyPath assay for early detection of lung cancer."

The 5, 10, 15, 20-tetrakis (carboxyphenyl) porphine, or TCPP, is the foundation for several Biomoda product lines and medical diagnostics. The company is completing data analysis for the pilot clinical trial of its first product, an in-vitro test for the detection of early-stage lung cancer, in which study volunteers provide deep-lung sputum samples to be screened for cancer cells with the CyPath assay. The company anticipates that results from the pilot study will provide the foundation for a pivotal clinical study leading to submission to the U.S. Food and Drug Administration (FDA) for approval of the commercial sale of Biomoda's technology.

Biomoda is seeking FDA approval of its cytology-based screening technology as a Class III medical device. Pending FDA approval, CyPath is for investigational use only. The company is also pursuing strategies to enter the European market, including filing for approval of a CE mark.

About Biomoda

Biomoda (www.biomoda.com) is a cancer diagnostics company focused on the development of accurate, inexpensive and noninvasive tests for the early detection of cancer in large populations. In addition to its first product for lung cancer, diagnostic assays for cervical, breast, colorectal, bladder, and oral cancers are targeted for development. Current research and development operations, laboratory functions and administrative offices are located in Albuquerque, N.M.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on estimates, projections, beliefs and assumptions of Biomoda management at the time of such statements and are not guarantees of future performance. Forward-looking statements involve risks and uncertainties in predicting future results and conditions. Actual results could differ materially from those projected in these forward-looking statements due to a variety of factors, including, without limitation, the acceptance by customers of our products, our ability to develop new products cost-effectively, our ability to raise capital in the future, the development by competitors of products using improved or alternative technology, the retention of key employees and general economic conditions. The forward-looking statements contained herein are also subject generally to other risks and uncertainties that are described from time to time in the Company's reports and registration statements filed with the Securities and Exchange Commission, including those under the heading "Risk Factors" in the Company's Annual Report on Form 10-K filed with the SEC on March 30, 2010. Forward-looking statements are made as of the date of this press release and are subject to change without notice.

Biomoda, Inc., Albuquerque
John Cousins, 505-821-0875